Literature DB >> 566540

Methylphenidate in 6-hydroxydopamine-treated developing rat pups. Effects on activity and maze performance.

B A Shaywitz, J H Klopper, J W Gordon.   

Abstract

In order to better devine the relationship between brain catecholaminergic mechanisms and the clinical syndrome of minimal brain dysfunction, we have developed an experimental model that has many of the features of the disorder seen in children. This model is effected by the preferential depletion of brain dopamine in 5-day-old rat pups following the intracisternal administration of 6-hydroxydopamine, and in the present investigation, we have examined the effects of methylphenidate hydrochloride (0.25 to 2.0 mg/kg) on activity levels and cognitive performance in normal and 6-hydroxydopamine treated animals. Methylphenidate therapy resulted in a significant increase in activity levels of normal rat pups 12 and 19 days of age; in contrast, methylphenidate administered to 6-hydroxydopamine-treated animals did not increase activity at 12 days of age and significantly reduced activity at 19 and 26 days. Methylphenidate had no effect on T-maze performance in normals, but significantly improved performance in 6-hydroxydopamine-treated animals. Our results suggest that the "paradoxical" response to methylphenidate found in 6-hydroxydopamine-treated rat pups may be the result of central denervation supersensitivity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 566540     DOI: 10.1001/archneur.1978.00500310065014

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  14 in total

Review 1.  Towards conceptualizing a neural systems-based anatomy of attention-deficit/hyperactivity disorder.

Authors:  Nikos Makris; Joseph Biederman; Michael C Monuteaux; Larry J Seidman
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

Review 2.  Animal models to guide clinical drug development in ADHD: lost in translation?

Authors:  Jeffery R Wickens; Brian I Hyland; Gail Tripp
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 3.  A controlled study of Tourette syndrome. VII. Summary: a common genetic disorder causing disinhibition of the limbic system.

Authors:  D E Comings
Journal:  Am J Hum Genet       Date:  1987-11       Impact factor: 11.025

4.  Differential sensitivity to acute administration of Ritalin, apomorphine, SCH 23390, but not raclopride in mice selectively bred for hyperactive wheel-running behavior.

Authors:  J S Rhodes; T Garland
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

5.  Dopaminergic but not noradrenergic mediation of hyperactivity and performance deficits in the developing rat pup.

Authors:  B A Shaywitz; M H Teicher; D J Cohen; G M Anderson; J G Young; P Levitt
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Developmental Deltamethrin Exposure Causes Persistent Changes in Dopaminergic Gene Expression, Neurochemistry, and Locomotor Activity in Zebrafish.

Authors:  Tiffany S Kung; Jason R Richardson; Keith R Cooper; Lori A White
Journal:  Toxicol Sci       Date:  2015-04-24       Impact factor: 4.849

7.  An evaluation of the young dopamine-lesioned rat as an animal model for minimal brain dysfunction (MBD).

Authors:  R E Thieme; H Dijkstra; J C Stoof
Journal:  Psychopharmacology (Berl)       Date:  1980-02       Impact factor: 4.530

Review 8.  Attention-deficit/hyperactivity disorder and attention networks.

Authors:  George Bush
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

9.  Adult zebrafish in CNS disease modeling: a tank that's half-full, not half-empty, and still filling.

Authors:  Darya A Meshalkina; Elana V Kysil; Jason E Warnick; Konstantin A Demin; Allan V Kalueff
Journal:  Lab Anim (NY)       Date:  2017-10-06       Impact factor: 12.625

10.  Intraventricular 6-hydroxydopamine in the newborn rat and locomotor responses to drugs in infancy: no support for the dopamine depletion model of minimal brain dysfunction.

Authors:  B A Pappas; J V Gallivan; T Dugas; M Saari; R Ings
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.